Compare Medpace Holdings Inc (MEDP) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard Growth Index Fund ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Vanguard Growth Index Fund ETF trades at $91.97 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 22.9× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 5,662,307). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| MEDP | VUG | |
|---|---|---|
Market Cap | $16.82B | $384.60B |
Volume | 223,093 | 5,662,307 |
Sector | Health | Sector/Thematic |
52-Week High | $630.19 | $92.64 |
52-Week Low | $393.42 | $70.00 |
Typical Hold Time | 14 Days | 47 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
VUG trades at $91.97, down 0.49% with a bullish technical signal supported by moving averages. The ETF holds dominant positions in mega-cap tech stocks including Nvidia, Apple, and Microsoft, which comprise over 36% of holdings. Recent financial media coverage highlights VUG's historical annual returns averaging 11-12% since its 2004 inception, positioning it as a long-term growth vehicle for investors with multi-decade horizons.
The outlook remains positive for long-term investors seeking growth exposure, though concentration in technology stocks presents sector-specific risks. Current technical levels show support at $89-91 with resistance at $92-94. The neutral oscillator readings suggest potential for consolidation near current levels before further directional movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
